




- (51) International Patent Classification:
A61K 38/14 (2006.01)
- (21) International Application Number:
PCT/US2012/038775
- (22) International Filing Date:
21 May 2012 (21.05.2012)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
61/487,971 19 May 2011 (19.05.2011) US
- (71) Applicant (for all designated States except US): **SAV-ARA, INC.** [US/US]; 5900 Shepherd Mountain Cove, Suite 2-205, Austin, TX 78759 (US).
- (72) Inventors; and
(75) Inventors/Applicants (for US only): **LORD, John** [US/US]; 6000 Front Royal Drive, Austin, TX 78746 (US). **JOUIKAINEN, Jaakko, Taneli** [FI/US]; 8852 Chalk Knoll Drive, Austin, TX 78735 (US). **SNYDER, Herman, E.** [US/US]; 308 Buchanan Drive, West Lafayette, IN (US). **SONI, Pravin** [US/US]; 1320 Bedford Avenue, Sunnyvale, CA 94097 (US). **KUO, Mei-chang** [US/US]; 1823 Middlefield Road, Palo Alto, CA 94303 (US).
- (74) Agent: **PICCARDO, Larissa**; Baker Botts LLP, 910 Louisiana Street, Houston, TX 77002 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

[Continued on next page]

(54) Title: DRY POWDER VANCOMYCIN COMPOSITIONS AND ASSOCIATED METHODS

FIGURE 3



(57) Abstract: Dry powder vancomycin compositions and methods for administering and preparing such compositions. A composition of the present disclosure may be administered to a subject via pulmonary administration in an amount effective to treat and/or prevent a bacterial infection in the subject. Administration of an effective amount of a composition of the present disclosure may be particularly useful in treating a gram-positive bacterial infection in a subject suffering from pneumonia, cystic fibrosis, bronchiectasis, or other chronic lung disease with a bacterial infection of the subject's airway and/or lung.



(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*